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Rett syndrome (RTT) is a neurodevelopmental disorder that affects girls due primarily to het-
erozygousmutations in the X-linked gene encodingmethyl-CpG binding protein 2 (MECP2).
Random X-chromosome inactivation (XCI) results in cellular mosaicism in which some cells
express wild-type (WT) MECP2 while other cells express mutant MECP2. The generation
of patient-speciﬁc human induced pluripotent stem cells (hiPSCs) facilitates the production
of RTT-hiPSC-derived neurons in vitro to investigate diseasemechanisms and identify novel
drug treatments. The generation of RTT-hiPSCs has been reported by many laboratories,
however, the XCI status of RTT-hiPSCs has been inconsistent. Some report RTT-hiPSCs
retain the inactive X-chromosome (post-XCI) of the founder somatic cell allowing isogenic
RTT-hiPSCs that express only the WT or mutant MECP2 allele to be isolated from the
same patient. Post-XCI RTT-hiPSCs-derived neurons retain this allele-speciﬁc expression
pattern ofWT or mutant MECP2. Conversely, others report RTT-hiPSCs in which the inac-
tive X-chromosome of the founder somatic cell reactivates (pre-XCI) upon reprogramming
into RTT-hiPSCs. Pre-XCI RTT-hiPSC-derived neurons exhibit random XCI resulting in cel-
lular mosaicism with respect toWT and mutant MECP2 expression. Here we review and
attempt to interpret the inconsistencies in XCI status of RTT-hiPSCs generated to date by
comparison to other pluripotent systems in vitro and in vivo and the methods used to ana-
lyze XCI. Finally, we discuss the relative strengths and weaknesses of post- and pre-XCI
hiPSCs in the context of RTT, and other X-linked and autosomal disorders for translational
medicine.
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INTRODUCTION
Rett syndrome [RTT (MIM 312750)] is a neurodevelopmental
disorder that primarily affects young girls at an incidence of 1 in
10,000 live female births (Chahrour and Zoghbi, 2007). RTT girls
develop normally until 6–18months of age when they enter devel-
opmental arrest. Clinical features of RTT include microcephaly,
stereotypic hand-washingmovements, autistic features, loss of lan-
guage, and mental retardation (Hagberg et al., 1983). Genetically,
over 95% of RTT patients carry a heterozygous mutation in the
X-linked gene encoding methyl-CpG binding protein 2 (MECP2;
Amir et al., 1999). MECP2 functions as a transcriptional regulator
by binding to the genome in a DNA methylation-dependent man-
ner via its methyl-CpG binding domain and recruiting chromatin
remodeling proteins via its transcriptional repression domain
(Nan et al., 1993, 1997, 1998; Chahrour et al., 2008; Ben-Shachar
et al., 2009; Skene et al., 2010). Other genes less commonly impli-
cated in RTT include CDKL5 and FOXG1, which are located on
chromosome X and 14, respectively (Scala et al., 2005; Ariani et al.,
2008).
A complexity of the RTT story is that theMECP2 gene is located
on the X-chromosome and is inﬂuenced by X-chromosome
inactivation (XCI). XCI is the mammalian strategy to equalize
X-linked gene dosage between XX females and XY males and
involves transcriptionally silencing themajority of genes on oneX-
chromosome in females (Escamilla-Del-Arenal et al., 2011; Yang
et al., 2011). This process initiates early in development; in the
embryo proper this occurs at about the time of implantation. At
its onset, XCI is random and either the maternally or paternally
inherited X-chromosome is silenced in each cell. Subsequently,
that X-chromosome remains the inactive X-chromosome (Xi)
throughout all future cell divisions (Escamilla-Del-Arenal et al.,
2011).
Regulation of XCI in both human and mouse requires the pres-
ence in cis of XIST, a 17 kb non-coding RNA (ncRNA; Brockdorff
et al., 1991; Brown et al., 1991, 1992; Penny et al., 1996). XIST
is only expressed from the Xi and its RNA product closely asso-
ciates with or “coats” the chromosome (Brown et al., 1991, 1992;
Clemson et al., 1996). Therefore, a key developmental event is
to upregulate Xist from the future Xi. Both cis and trans-acting
factors have been identiﬁed in mouse through the use of trans-
genes and targeted deletions (Donohoe et al., 2009; Barakat et al.,
2011). In cis Xist is positively and negatively regulated by adja-
cent sequences and transcripts that include at least four ncRNAs
(Debrand et al., 1999; Lee et al., 1999; Ogawa and Lee, 2003; Augui
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et al., 2007; Tian et al., 2010; Barakat et al., 2011). Perhaps the
best characterized negative regulator is Tsix, an ncRNA antisense
to Xist (Lee et al., 1999). While XIST is conserved between human
and mouse, at least some events at the onset of XCI must differ
between the species, as most ncRNAs including TSIX are poorly
conserved (Chureau et al., 2002; Migeon et al., 2002).
Upon Xist upregulation, the Xi is heavily epigenetically remod-
eled, in many ways similar to other silenced genes throughout the
genome. Epigenetic marks associated with the Xi include CpG
island promoter DNA methylation (Hellman and Chess, 2007;
Sharp et al., 2011), incorporation of histone variant MacroH2A
(Costanzi and Pehrson, 1998), and modiﬁcation of core histones
(Keohane et al., 1996; de Napoles et al., 2004; Kohlmaier et al.,
2004). An early event that follows XIST accumulation is the
recruitment of the polycomb complex PRC2 that induces histone
H3 trimethylation at lysine 27 (H3K27me3; Plath et al., 2003; Silva
et al., 2003; Marks et al., 2009). Other epigenetic features, such
as DNA methylation, accumulate later, and are important in the
maintenance of XCI. Altogether these many alterations function
with XIST to create a silenced nuclear compartment (Chow et al.,
2010) that is spatially sequestered to the periphery of the nucleus
and is cytologically recognizable as the darkly staining Barr body
(Barr and Bertram, 1949).
Because of the random nature of XCI, RTT females are mosaic
with both wild-type (WT) cells that inactivate the X-chromosome
harboring the mutant allele and mutant cells that have inactivated
the WT allele. Although XCI is random in most cases resulting
in a 50:50 XCI ratio, it can deviate from this ratio. This results
in a wide range of clinical presentations for RTT patients, even
among related individuals carrying identical MECP2 mutant alle-
les, depending on the extent of favorable skewing (Archer et al.,
2007).
Onemodel to studyRTT is to employ the technology of induced
pluripotency. Human induced pluripotent stem cells (hiPSCs) are
pluripotent stem cells generated from somatic cells by the intro-
duction of a combination of pluripotency associated genes such as
OCT4, SOX2, along with either KLF4 and c-MYC or NANOG and
LIN28 via retroviral or lentiviral vectors (Takahashi et al., 2007;Yu
et al., 2007; Park et al., 2008). Most importantly, hiPSCs are similar
to human embryonic stem cells (hESCs) functionally as they are
pluripotent and can potentially differentiate into any desired cell
type when provided with the appropriate cues, but do not have
the ethical issues surrounding hESCs (Murry and Keller, 2008).
For these reasons, hiPSCs have huge potential in translational
medicine such as disease modeling, drug screening, and cellular
therapy. Indeed, patient-speciﬁc hiPSCs have been generated for
a multitude of diseases, including many with a neurological basis,
in which disease phenotypes have been recapitulated in vitro and
proof-of-principle drug screening has been performed (Saha and
Jaenisch, 2009; Ross and Ellis, 2010; Han et al., 2011; Marchetto
et al., 2011; Zhu et al., 2011).
The generation of patient-speciﬁc hiPSCs from RTT girls has
been an area of intense research as several groups have reported
the generation of such cells (Hotta et al., 2009; Marchetto et al.,
2010; Amenduni et al., 2011; Ananiev et al., 2011; Cheung et al.,
2011; Kim et al., 2011; Pomp et al., 2011). RTT-hiPSCs gener-
ated by different groups have similar properties as they carry
pathogenic mutations in MECP2 or CDKL5 and are pluripo-
tent in vitro and in vivo. Most importantly, RTT-hiPSCs can be
differentiated into affected neurons and exhibit RTT-associated
phenotypes in vitro and can be rescued by transgene expression
or drug treatments. However, with the generation of RTT-hiPSCs
from multiple groups, the XCI status of RTT-hiPSCs, and more
generally, female hiPSCs, has been variable. Some groups (Amen-
duni et al., 2011; Ananiev et al., 2011; Cheung et al., 2011; Pomp
et al., 2011) reported the generation of RTT-hiPSCs that retain the
Xi (post-XCI) from the founder somatic cell it was derived from,
while others (Kim et al., 2009; Marchetto et al., 2010) reported
the generation of some RTT-hiPSCs that reactivate the Xi of the
founder somatic cell and hence carry two active X-chromosomes
(pre-XCI).
Here we review the differences in XCI status reported in the
RTT-hiPSC literature and attempt to discuss the differences and
interpret the inconsistencies between post- and pre-XCI RTT-
hiPSCs by considering the XCI status described in other pluripo-
tent systems from mouse and human, both in vitro and in vivo.
Given the variations in XCI status reported in the human pluripo-
tent stem cell (hPSC) literature, we discuss different methods to
accurately evaluate the XCI status. We discuss the advantages and
disadvantages of post- and pre-XCI RTT-hiPSCs for translational
medicine. Finally,we discuss the signiﬁcant impactXCI has onhiP-
SCs generated from female individuals, especially those affected by
X-linked disorders other than RTT, but also apparently unaffected
females who may or may not be carriers of X-linked mutations,
and perhaps also autosomal disorders.
XCI IN THE MOUSE PLURIPOTENT SYSTEM
To place the relationship between XCI and RTT-hiPSCs into con-
text, it is important to consider the XCI status of other pluripo-
tent stem cell systems such as hiPSCs, hESCs, mouse induced
pluripotent stem cells (miPSCs), and mouse embryonic stem
cells (mESCs), and how they compare to their in vivo counter-
parts (Fan and Tran, 2011; van den Berg et al., 2011; Minkovsky
et al., 2012). At embryonic day (e)3.5 of mouse embryogenesis,
preimplantation epiblast cells carry two active X-chromosomes
(Xa; Rastan, 1982; Takagi et al., 1982). Subsequently, random
XCI ensues at gastrulation at around e5.5 (Rastan, 1982; Takagi
et al., 1982). Xist RNA is expressed at low levels on both Xa
until random XCI ensues in which the Xa represses Xist RNA
while the Xi upregulates Xist RNA (Mak et al., 2004; Okamoto
et al., 2004). Consistently, mESCs isolated from the preimplanta-
tion epiblast cells of the blastocysts at e3.5 carry two Xa, expressing
Xist RNA in a biallelic manner (Evans and Kaufman, 1981; Mar-
tin, 1981; Lee et al., 1999). Similarly, the generation of miPSCs
is accompanied by reactivation of the Xi in the founder somatic
cell and hence carry two Xa followed by random XCI upon dif-
ferentiation (Maherali et al., 2007; Stadtfeld et al., 2008a). This
indicates that the generation of miPSCs involves the complete
erasure of XCI. Subsequently, pluripotent stem cells known as
mouse epiblast stem cells (mEpiSCs) have been isolated from
the postimplantation epiblast at around e5.5 (Brons et al., 2007;
Tesar et al., 2007). mEpiSCs carry an Xi similar to their in vivo
counterpart in which random XCI has already ensued (Guo et al.,
2009).
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XCI IN hESCs
HESCs are isolated from the preimplantation epiblast cells of the
blastocyst (Thomson et al., 1998; Reubinoff et al., 2000). Stud-
ies of XCI in human embryos are much more limited than in
mouse, but intriguingly suggest differences in XCI timing and
XIST RNA expression (van den Berg et al., 2009; Okamoto et al.,
2011). Unlike mouse, XIST RNA is upregulated in preimplanta-
tion blastocysts (van den Berg et al., 2009; Okamoto et al., 2011).
The role of XIST RNA association in XCI at this early timepoint
is not yet clear as two recent studies have shown different results;
female preimplantation blastocysts had monoallelic XIST RNA
upregulation and XCI hallmarks in one study (van den Berg et al.,
2009), whereas another reported XIST RNA accumulation from
all X-chromosomes, males and females, without gene silencing
(Okamoto et al., 2011).Whether such heterogeneity exists between
different human embryos or variability is introduced upon cul-
turing, it appears that human XIST RNA coating and XCI are not
strictly coupled.
Similarly, the XCI status of hESCs has been highly variable
(Dhara and Benvenisty, 2004; Enver et al., 2005; Hoffman et al.,
2005; Adewumi et al., 2007; Hall et al., 2008; Shen et al., 2008;
Silva et al., 2008; Liu and Sun, 2009; Dvash et al., 2010; Diaz
Perez et al., 2012). The XCI status of hESCs can be categorized
into three classes as proposed by Lee and colleagues (Silva et al.,
2008). Class I hESCs are in a pre-XCI state, express X-linked genes
in a biallelic fashion, lack XCI marks such as XIST RNA and
H3K27me3, and initiate XCI upon differentiation accompanied
by upregulation of the same marks (Dhara and Benvenisty, 2004;
Hall et al., 2008; Silva et al., 2008; Dvash et al., 2010; Diaz Perez
et al., 2012). The most deﬁning feature of Class I hESCs is initi-
ation of random XCI upon differentiation, resulting in random
monoallelic expression of X-linked genes (Dhara and Benvenisty,
2004). To date, few Class I hESCs have been isolated using con-
ventional hESC conditions in atmospheric oxygen concentrations
(20% O2) and basic FGF (bFGF)/knockout serum (KOSR; Dhara
and Benvenisty, 2004; Hall et al., 2008; Silva et al., 2008; Dvash
et al., 2010; Diaz Perez et al., 2012). Most hESCs have initiated XCI
and thus are in a post-XCI state that can be subdivided accord-
ing to the presence (Class II) or absence (Class III) of XCI marks
such as XIST RNA and H3K27me3 (Hoffman et al., 2005; Hall
et al., 2008; Shen et al., 2008; Silva et al., 2008; Liu and Sun, 2009;
Dvash et al., 2010; Diaz Perez et al., 2012). Class II hESCs carry an
Xi with a non-random skewing pattern resulting in non-random
monoallelic expression of X-linked genes (Hoffman et al., 1987;
Hall et al., 2008; Shen et al., 2008; Silva et al., 2008; Liu and Sun,
2009). This is likely due to clonal expansion of cells with one
of the parental X-chromosomes inactivated (Liu and Sun, 2009).
Class III hESCs can also retain an Xi despite the absence of such
XCI marks (Shen et al., 2008; Silva et al., 2008; Diaz Perez et al.,
2012). This indicates that XCI marks are not an accurate evalu-
ation of XCI status in hESCs. Although most genes stay silenced
in Class III hESCs, previously silenced X-linked genes may reac-
tivate on a small scale accompanied by DNA hypomethylation of
their promoters (Shen et al., 2008; Dvash et al., 2010). A recent
analysis suggests that this reactivation may occur on a much
larger scale with entire regions of the X-chromosome arms being
reactivated (Bruck and Benvenisty, 2011). Overall, such sporadic
X-linked gene reactivation appears higher than in somatic cells
but is likely akin to levels in mouse cells that have lost Xist RNA
(Wutz and Jaenisch, 2000; Csankovszki et al., 2001; Zhang et al.,
2007).Adeﬁning feature of Class III hESCs is that theyhave already
initiated XCI despite having lost the XCI marks. Therefore, they
cannot initiate XCI again and do not upregulate XCI marks upon
differentiation (Shen et al., 2008; Silva et al., 2008; Dvash et al.,
2010; Diaz Perez et al., 2012).
HESCs with these three classes of XCI are hypothesized to be in
a continuum and interrelated (Silva et al., 2008; Diaz Perez et al.,
2012). It is thought that Class I hESCs represent the most pris-
tine pluripotent stem cells present in the human blastocyst which
contains two Xa (Okamoto et al., 2011). However, the culturing
of Class I hESCs can result in a spontaneous transition into Class
II hESCs in which XCI initiates and upregulates XCI marks (Silva
et al., 2008). Class II hESCs, upon culture and/or cellular stresses
such as freeze/thaw cycles, can also lose XCI marks such as XIST
RNA and repressive chromatin marks, and thus transition into
Class III hESCs (Hall et al., 2008; Shen et al., 2008; Silva et al.,
2008; Dvash et al., 2010; Diaz Perez et al., 2012). Together, these
data suggest that the XCI status of hESCs is subject to extensive
epigenetic ﬂuidity with respect to XCI.
Given the lack of correlation between XCI marks and XCI sta-
tus in hESCs, Benvenisty and colleagues used an X-chromosome
wide microarray analysis to investigate the expression level of a
large number of X-linked genes as a functional read out of XCI
in hPSCs, including hESCs and hiPSCs (Bruck and Benvenisty,
2011). Their microarray analysis revealed that hPSCs can be clas-
siﬁed into No XCI, Full XCI, or Partial XCI categories. These three
categories are deﬁned by the proportion of X-linked genes that
express twofold (i.e., two Xa) in comparison to male hPSCs. No
XCI indicates most X-linked genes (>85%) express at twofold
levels compared to male hPSCs. Full XCI indicates few X-linked
genes (<15%) express at twofold levels compared to male hPSCs.
Partial XCI indicates reactivation of a proportion (15–85%) of
X-linked genes. Interestingly, it was observed that the location of
partial inactivation tends to surround the XIST locus. XIST RNA
expression, by quantitative reverse transcription polymerase chain
reaction (qRT-PCR), was only partially correlated with these three
states and would not have been able to distinguish between Full
XCI and Partial XCI states. The term No XCI used in this study is
ﬁtting as it is not clearwhether these hPSCswere generated directly
with a pre-XCI phenotype, or from partial-XCI hPSCs that have
reactivated X-linked genes on a chromosomal level resulting in an
apparent pre-XCI phenotype. Thus, X-chromosome wide expres-
sion analysis via microarray could be used in determining the XCI
status of the entire X-chromosome, but this method alone cannot
identify pre-XCI hPSCs.
The two classiﬁcations above proposed by Lee and colleagues
and Benvenisty and colleagues are both invaluable (Silva et al.,
2008; Bruck and Benvenisty, 2011). XCI based solely on XCI
marks such as XIST RNA and H3K27me3 is insufﬁcient and
suggests that candidate X-linked gene expression analysis in an
allele-speciﬁc manner is crucial to functionally read out the XCI
status of hESCs. In contrast, Benvenisty and colleagues catego-
rized the hPSCs in their study based solely on expression of the
entire X-chromosome. For the purpose of this review and to be
www.frontiersin.org March 2012 | Volume 3 | Article 24 | 3
Cheung et al. XCI in RTT-hiPSCs
consistent with the terminology used in most of the hESC conver-
sion studies and the hiPSC literature discussed below, we prefer
to categorize hPSCs as either pre-XCI or post-XCI. Pre-XCI hPSCs
are identical to Class I hPSCs and carry two Xa without any signs
of XCI initiation. Upon differentiation, pre-XCI hPSCs will initi-
ate XCI and upregulate XCI marks in a random pattern resulting
in random monoallelic expression of X-linked genes. Post-XCI
hPSCs encompass both Class II and III hPSCs in that they have
already initiated the process of XCI and carry an Xi regardless of
the presence or absence of XCI marks. Differentiation of post-XCI
hPSCs will yield a non-random XCI skewing pattern resulting in
a non-random monoallelic expression of X-linked genes.
The largely post-XCI state of hESCs may be explained by the
fact that they are thought to represent a cell type that is develop-
mentally later than mESCs (Rossant, 2008; Silva and Smith, 2008;
Nichols and Smith, 2009). It is thought that although hESCs are
isolated from the preimplantation epiblast of the blastocyst, where
there could be two Xa (Okamoto et al., 2011), they may in fact
represent cells of the postimplantation epiblast where XCI has
likely ensued as in the murine postimplantation epiblast (Rastan,
1982; Takagi et al., 1982). This is supported by the fact that hESCs
are more similar to the murine in vitro counterpart of the postim-
plantation epiblast,mEpiSCs, than themurine in vitro counterpart
of the preimplantation epiblast, mESCs. The pluripotent state of
mESCs is maintained by cytokines including leukemia inhibitory
factor (LIF) and bone morphogenic protein (BMP) 4 which acti-
vates the Jak/Stat pathway and induces inhibitor-of-differentiation
proteins, respectively (Smith et al., 1988; Williams et al., 1988;
Niwa et al., 1998; Matsuda et al., 1999; Ying et al., 2003). On the
other hand, hESCs, similar to mEpiSCs, are maintained by ﬁbrob-
last growth factor (FGF) which induces mitogen-activated protein
kinases Erk1/2 and activin/nodal signaling (Thomson et al., 1998;
Vallier et al., 2004; James et al., 2005; Brons et al., 2007; Kunath
et al., 2007; Stavridis et al., 2007; Tesar et al., 2007). Furthermore,
gene expression proﬁling reveals similarities between hESCs and
mEpiSCs, but distinct frommESCs (Tesar et al., 2007). Therefore it
is not surprising that hESCs are mostly in a post-XCI state similar
to mEpiSCs (Guo et al., 2009).
CONVERSION OF MOUSE AND HUMAN PLURIPOTENT STEM
CELLS TO THE NAÏVE STATE
To explain why hESCs isolated from the preimplantation epiblast
would more closely resemble cells isolated from the postimplan-
tation epiblast, it is important to consider that upon isolation,
they are not frozen in developmental time in culture (Nichols and
Smith, 2009). Indeed, it may be unnatural for hESCs (and mESCs)
to expand in a pre-XCI state as this does not occur in development
(Hall et al., 2008). Therefore, hESCs may preferentially undergo
XCI during derivation and expansion. On the other hand, female
mESCs appear to utilize a different strategy to accommodate for
two Xa by frequently losing one X-chromosome (Zvetkova et al.,
2005). Therefore, although hESCs may have a pre-XCI status dur-
ing their isolation, they may continue to progress into the postim-
plantation epiblast stage (representative of mEpiSCs) and become
post-XCI. To distinguish these two pluripotent stages, mESCs are
classiﬁed to be in anaïve state,whereasmEpiSCs (and likely hESCs)
are classiﬁed to be in a primed state (Silva and Smith, 2008;Nichols
and Smith, 2009). Further evidence that these two stages are bio-
logically relevant comes from experiments that show mESCs and
mEpiSCs are distinct states that can be converted between one
another. When cultured in conditions consisting of small mole-
cules (known as the 2i cocktail) that inhibit FGF stimulation of
mitogen-activated protein kinases Erk1/2 and constitutive activity
of glycogen synthase kinase-3, mESCs are maintained in the most
pristine naïve state of pluripotency (Ying et al., 2008). On the other
hand, mESCs can be differentiated into mEpiSCs when placed in
the culture conditions of the latter while introduction of a Klf4
transgene and growth in 2i conditions can convert mEpiSCs back
to a naïve state reminiscent of mESCs (Guo et al., 2009). These
studies suggest that the external milieu to which pluripotent stem
cells are exposed has a signiﬁcant impact on their pluripotent state
and their XCI status.
Since the identiﬁcation of optimal conditions for naïve pluripo-
tency for mESCs and the hypothesis that hESCs may be more
similar to mEpiSCs, attempts have been made to deﬁne condi-
tions to isolate hESCs in a more naïve state of pluripotency in
order to derive hESCs equivalent to mESCs. One approach that
was examined was the isolation of hESCs under physiological oxy-
gen concentrations (5% O2; Lengner et al., 2010). It was proposed
that the atmospheric oxygen concentration (20% O2), in which
conventional propagation of hESCs is performed is hyperoxic in
comparison to the blastocyst in vivo, and may represent a sub-
optimal culture condition for hESCs. Indeed, when hESCs were
established from human embryos in 5% O2, pre-XCI hESCs were
derived that were capable of random XCI upon differentiation. On
the other hand, hESCs derived under 20% O2 were all post-XCI
with a non-random monoallelic expression pattern. Furthermore,
when 5% O2 pre-XCI hESCs were subsequently exposed to 20%
O2 or cellular stress (such as freeze/thaw), XCI ensued. This sug-
gests that conventional hESC culture conditions (i.e., 20%O2) and
other cellular stresses are detrimental for capturing and main-
taining hESCs in a pre-XCI state. Conversely, post-XCI hESCs
were not able to go through X-chromosome reactivation (XCR)
when placed back in hypoxic conditions or after treatment with
antioxidants. This suggests that XCI is irreversible (Lengner et al.,
2010) or that other strategies are required for XCR (Hanna et al.,
2010).
To that end, primed hESCs, with an Xi, have been con-
verted to naïve hESCs, with two Xa, by continuous transgene
expression of OCT4 and KLF4, or KLF4 and KLF2, combined
with deﬁned conditions including 2i and LIF (Hanna et al.,
2010). The converted naïve hESCs revert back to a primed
state when placed back in conventional hESC conditions (bFGF
and KOSR) demonstrating that the naïve and primed states are
interchangeable in hESCs when given the correct environmen-
tal cues along with exogenous transgenes. However, naïve hESCs
were only maintained under continuous transgene expression
demonstrating the need for further optimal culture conditions
without genetic manipulation to capture this naïve pluripo-
tency state. To this end, the authors identiﬁed Forskolin, a pro-
tein kinase A pathway agonist which induces the expression of
KLF4 and KLF2. Forskolin can substitute for the continuous
ectopic transgene expression although its effect was transient
as naïve hESCs were only maintained for a limited number of
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passages. Similar methods in generating naïve hiPSCs can also
be achieved by the exogenous transgene expression of OCT4,
SOX2,KLF4, c-MYC, and NANOG in the presence of LIF although
the XCI status of these cells was not examined (Buecker et al.,
2010). Together, these data suggest that XCR is possible via the
introduction of exogenous transgenes. However, if naïve hESCs
were to be used clinically, non-integrating approaches will be
preferred.
To that end, two small molecules, Sodium Butyrate (SB) and
3-deazaneplanocin A (DZNep), have been recently identiﬁed to
promote the conversion and isolation of Class I hESCs (Diaz Perez
et al., 2012). Note that here we employ the Class I, II, III, system
to be consistent with the description by the authors (Diaz Perez
et al., 2012). SB is a histone deacetylase inhibitorwhich can convert
hESCs to a more naïve state similar to mESCs (Ware et al., 2009).
DZNep depletes enhancer of zeste homolog2 (EZH2) resulting in
a global decrease of H3K27me3 (Tan et al., 2007; Fiskus et al.,
2009; Musch et al., 2010). When Class II hESCs were treated with
SB or SB+DZNep, Class I hESCs emerged as indicated by the
absence of H3K27me3 and lack of H3K4me3 exclusion on the
X-chromosome, indicative of XCR (Diaz Perez et al., 2012). How-
ever, this effect was not 100% efﬁcient, as only a proportion of
cells within a culture of Class II hESCs can be converted. In con-
trast, Class III hESCs were not able to proceed through XCR by
the same treatment. Conversely, treatment with SB or DZNep or
both prevented Class I hESCs from transitioning into Class II, at
least during the time frame (10 passages) analyzed by the authors.
Altogether, these data suggest that although pre-XCI hESCs can
be isolated, suboptimal culture conditions prevent facile main-
tenance of naïve hESCs in a pre-XCI state (Hanna et al., 2010;
Lengner et al., 2010; Diaz Perez et al., 2012). Hence, hESCs con-
tinue to progress along the developmental timeline to stabilize in
a primed state as post-XCI hESCs (Nichols and Smith, 2009).
XCI IN hiPSCs
The XCI status of female hiPSCs has been extensively studied
by Plath and colleagues. They found that most female hiPSCs in
their study were post-XCI as indicated by XIST RNA and enrich-
ment of the polycomb repressive complex EZH2 which mediates
enrichment of H3K27me3, and depletion of active histone marks
H3K18ac and H3K4me3 from the Xi (Tchieu et al., 2010). Fur-
thermore, post-XCI hiPSCs expressed the X-linked genes XIST,
ATRX, and PDHA1 in a non-random monoallelic fashion revealed
by allele-speciﬁc SNP analysis. This suggests that during repro-
gramming, hiPSCs inherit the Xi from the founder somatic cell.
Post-XCI hiPSCs were prone to losing XCI marks such as XIST
RNA, EZH2,macroH2A1, and H4K20me1 upon extended passag-
ing. However, these hiPSCs retained a transcriptionally silent Xi.
This reiterates that evaluation of XCI marks such as XIST RNA
and chromatinmarks and theirmediators is not sufﬁcient to deter-
mine XCI status in hPSCs (Shen et al., 2008; Silva et al., 2008;
Lengner et al., 2010; Diaz Perez et al., 2012). Finally, these data
suggest that the non-random XCI nature of female hiPSCs can be
exploited to generate isogenic control (expressingWTprotein) and
mutant (expressing mutant protein) hiPSCs from the same indi-
vidual carrying heterozygousmutations inX-linked genes. Indeed,
the authorswere able to isolate isogenic control andmutant hiPSCs
from Duchenne muscular dystrophy (DMD) carriers with a het-
erozygous mutation in the X-linked DYSTROPHIN gene (Tchieu
et al., 2010).
Several groups have generated hiPSCs fromRTTpatients (Mar-
chetto et al., 2010; Amenduni et al., 2011; Ananiev et al., 2011;
Cheung et al., 2011; Kim et al., 2011; Pomp et al., 2011). The het-
erozygous mutation of the X-linked gene MECP2 in RTT-hiPSCs
has prompted extensive analysis of their XCI status as it directly
affects their functional read out (Figure 1). Post-XCI RTT-hiPSCs
with non-random XCI will yield isogenic WT or mutant MECP2
expressing RTT-hiPSCs. Differentiation of post-XCI RTT-hiPSCs
will yield cultures that maintain this non-random monoallelic
expression pattern allowing the direct comparison of WT and
mutant neurons (Figure 1A). Conversely, pre-XCI RTT-hiPSCs
will carry two Xa and upon differentiation would yield a mosaic
culture of WT or mutant MECP2 expressing neurons similar to
RTT patients (Figure 1B).
POST-XCI RTT-hiPSCs
Four studies report the generation of RTT-hiPSCs in a post-XCI
state (Amenduni et al., 2011; Ananiev et al., 2011; Cheung et al.,
2011; Pomp et al., 2011). In our study,X-chromosome activity and
mosaicism were evaluated by XIST RNA-FISH and H3K27me3
immunoﬂuorescence (IF; Cheung et al., 2011). We found RTT-
hiPSCs that were positive or negative for these XCI marks within
the same culture. The RTT-hiPSCs that are negative for XCI marks
could be interpreted as: (1) loss of an X-chromosome, (2) two Xa,
or (3) an Xi that has subsequently lost XCI marks but remains
inactive. We rejected the ﬁrst hypothesis as RTT-hiPSCs carried
two X-chromosomes as assayed by X-centromere DNA-FISH and
karyotyping. The second possibility, two Xa,was ruled out as RTT-
hiPSC-derived neurons had a non-random XCI skewing pattern,
as measured by the androgen receptor methylation (AR) assay
(Allen et al., 1992), which is inconsistent with the presence of two
Xa which would have otherwise resulted in random XCI upon
differentiation. Therefore we favored the explanation that RTT-
hiPSCs negative for XCI marks are post-XCI with an Xi that has
subsequently lost those marks. Post-XCI RTT-hiPSCs had non-
random XCI consistent with the fact that reprogramming retains
the Xi in the founder somatic cell (Cheung et al., 2011). Finally,
expression analysis, by direct sequencing of cDNA or qRT-PCR
usingWTMECP2-speciﬁc primers, conﬁrmed that post-XCIRTT-
hiPSCs and their neuronal derivatives expressed WT or mutant
MECP2 in non-random monoallelic manner. This conﬁrms the
ﬁndings by Plath and colleagues that the non-random monoal-
lelic post-XCI status of female hiPSCs can be exploited to generate
isogenic control (expressing WT MECP2) and mutant (express-
ing mutant MECP2) hiPSCs from the same individual (Tchieu
et al., 2010). Similarly, Renieri and colleagues and Chang and col-
leagues isolated isogenic control and mutant RTT-hiPSCs from
some female patients carrying heterozygous mutations in the X-
linked CDKL5 gene and MECP2, respectively (Amenduni et al.,
2011; Ananiev et al., 2011). RTT-hiPSCs were post-XCI as they
displayed non-random XCI skewing by AR assay and expressed
CDKL5 orMECP2 in a non-randommonoallelicmanner allowing
the isolation of isogenic control and mutant RTT-hiPSCs. Alto-
gether, these studies demonstrate that post-XCI RTT-hiPSCs can
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FIGURE 1 | Generation of pre- and post-XCI RTT-hiPSCs. RTT-hiPSCs
have been generated from RTT-ﬁbroblasts isolated from RTT patients who
carry a heterozygous mutation in MECP2. The reprogramming of
RTT-ﬁbroblasts have yielded RTT-hiPSCs that are in a post-XCI (A) or
pre-XCI (B) state. Post-XCI RTT-hiPSCs retains an Xi from the founder
somatic cell and express MECP2 in a non-random monoallelic manner.
This results in the generation of mutant and isogenic control RTT-hiPSCs
depending on whether the Xi harbors theWT or mutant MECP2. The
differentiation of post-XCI RTT-hiPSCs retains this XCI pattern allowing
homogeneous cultures of neurons that expressWT or mutant MECP2.
Pre-XCI RTT-hiPSCs carry two Xa and express theWT and mutant MECP2
in a biallelic fashion. The differentiation of RTT-hiPSCs into neurons initiate
random XCI resulting in a mosaic culture of neurons that either express
WT or mutant MECP2. Mut, mutant.
be isolated, and become a particularly strong model system that
allows direct comparison of mutant and isogenic control RTT-
hiPSCs from the same individual (Amenduni et al., 2011; Ananiev
et al., 2011; Cheung et al., 2011).
Colman and colleagues examined the dynamics of XCI dur-
ing RTT-hiPSC establishment in order to implement strategies
that were necessary to isolate pairs of mutant and isogenic con-
trol RTT-hiPSCs (Pomp et al., 2011). Similar to the RTT-hiPSCs
described above (Amenduni et al., 2011; Ananiev et al., 2011; Che-
ung et al., 2011), RTT-hiPSCs displayed a non-random post-XCI
pattern (Pomp et al., 2011). However, they were unable to iso-
late pairs of mutant and isogenic control post-XCI RTT-hiPSCs
from the same individual. For example, RTT-hiPSCs generated
fromp.T158M MECP2 ﬁbroblasts were all expressingWT MECP2,
while RTT-hiPSCs generated from 1155del32 MECP2 ﬁbroblasts
were all expressingmutantMECP2. They referred to the expressing
and silent X-chromosome as dominant (Xd) and unfavored (Xu),
respectively. Fibroblasts carrying an active Xd had a higher repro-
gramming efﬁciency (50∼ 100 fold) than those carrying an active
Xu. Interestingly, although early passage ﬁbroblasts were mosaic
for the two MECP2 alleles, serial passaging skewed the XCI toward
the Xd in a predictable manner mirrored during reprogramming.
This loss of mosaicismwas due to a proliferative advantage of those
ﬁbroblasts carrying an active Xd, and an increase in DNA damage
in ﬁbroblasts carrying an active Xu. The authors hypothesized that
this was a consequence of critically shortened telomeres resulting
in telomere-associated DNA damage and senescence in ﬁbroblasts
expressing Xu.
To address the role of telomeres in reprogramming, Colman
and colleagues introduced an exogenous telomerase reverse tran-
scriptase (TERT) transgene into ﬁbroblasts to prevent skewing
(Pomp et al., 2011). Such TERT expression allowed the generation
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of isogenic control and mutant RTT-hiPSCs from the same indi-
vidual. The reprogramming bias toward ﬁbroblasts with an active
Xd can also be overcome by increasing the number of hiPSC lines
characterized, or by subcloning the ﬁbroblasts expressing Xu prior
to reprogramming. However, this remedy will not work on ﬁbrob-
lasts with a totally skewed population in which all the ﬁbroblasts
with an active Xu may have already been lost. To restore this lost
population, they promoted naïve conversion of post-XCI RTT-
hiPSCs to pre-XCI RTT-hiPSCs by culturing in 2i/LIF conditions
as discussed above (Hanna et al., 2010). The resulting pre-XCI
RTT-hiPSCs expressed both the WT and mutant MECP2 allele
in a biallelic fashion and lost H3K27me3 suggesting XCR (Pomp
et al., 2011). Upon differentiation, pre-XCI RTT-hiPSCs under-
went random XCI and generated a mosaic culture of ﬁbroblasts
that expressed either the WT or mutant MECP2, thereby restoring
the lost population expressingXu.Althoughnot demonstrated, the
reprogramming of such ﬁbroblasts expressing Xu should also yield
isogenic control and mutant post-XCI RTT-hiPSCs. Together,
these data suggest that there is an inherent difference in the two
parental X-chromosomes, independent of the MECP2 mutation,
which impacts the reprogramming efﬁciency of any given cell. This
will ultimately impact one’s ability to generate isogenic control
and mutant post-XCI RTT-hiPSCs from ﬁbroblasts that have been
extensively passaged. For example, we were only able to isolate iso-
genic control and mutant RTT-hiPSCs from primary ﬁbroblasts
carrying the Δ3–4 MECP2 mutation (Cheung et al., 2011). Sim-
ilarly, Chang and colleagues and Renieri and colleagues isolated
isogenic control RTT-hiPSCs from primary Q347X-ﬁbroblasts
(Amenduni et al., 2011), and primary R294X-ﬁbroblasts (Ananiev
et al., 2011), respectively. This is consistent with the ﬁndings by
Colman and colleagues who suggest that the mosaic ﬁbroblast cul-
ture is lost overtime. Therefore, the generation of isogenic control
and mutant post-XCI RTT-hiPSCs should be more efﬁcient from
primary ﬁbroblasts at earlier passages while the mosaic culture is
still present (Pomp et al., 2011).
PRE-XCI RTT-hiPSCs
Two groups have isolated pre- and post-XCI RTT-hiPSCs (Mar-
chetto et al., 2010; Kim et al., 2011). To evaluate the XCI status of
RTT-hiPSCs, Muotri and colleagues performed XIST RNA-FISH
and H3K27me3 IF (Marchetto et al., 2010). They reported both
pre- and post-XCI RTT-hiPSCs based on the absence or presence
of these XCI marks, respectively, in which the former was the
focus for the rest of their study. Their pre-XCI RTT-hiPSCs ini-
tiated XCI upon differentiation into neurons as they induced the
expression of XIST RNA and H3K27me3. To determine whether
there was random XCI, the authors focused on RTT-hiPSCs from
a patient carrying an 1155del32 mutation which results in a trun-
cated MECP2 protein. By using a C-terminus MECP2 antibody,
they could distinguish between the WT and mutant protein via IF.
The pre-XCI RTT-hiPSCs were homogeneously MECP2-positive,
suggesting biallelic expression of MECP2 as expected for two
Xa. When pre-XCI RTT-hiPSCs were differentiated into neurons,
there was a mosaic expression of MECP2-positive and -negative
neurons. Furthermore, western blot analysis of pre-XCI RTT-
hiPSC-derived neurons showed a reduction in MECP2 protein
levels. Based on these ﬁndings, the authors conclude that pre-XCI
RTT-hiPSCs initiate random XCI upon differentiation. However,
the AR assay revealed that the pre-XCI RTT-hiPSC-derived neu-
rons showed extreme skewing (96:4 to 98:2) inconsistent with
random XCI. Thus, the neurons preferentially inactivated the AR
gene on one parental X-chromosome but not randomly as would
be expected. These results have been interpreted as suggesting that
the neurons preferentially inactivated the parental X-chromosome
carrying WT MECP2 (Walsh and Hochedlinger, 2010). However,
it is also possible that during neuronal differentiation, dividing
neuronal progenitors carrying a particular Xi may have a prolif-
erative advantage causing the observed skewing in the resulting
neurons (Pomp et al., 2011).
Park and colleagues were also able to isolate both pre- and
post-XCI RTT-hiPSCs (Kim et al., 2011). Pre-XCI and post-XCI
RTT-hiPSCs expressed MECP2 in a biallelic and monoallelic man-
ner, respectively. Furthermore, the authors measured the total
transcript levels of MECP2 via qRT-PCR and found that pre-XCI
RTT-hiPSCs expressed MECP2 twofold in comparison to male
hESCs while post-XCI RTT-hiPSCs expressed MECP2 at simi-
lar levels compared to male hESCs. With regards to XCI marks,
pre-XCI and post-XCI RTT-hiPSCs were absent and present for
H3K27me3, respectively. Based on these ﬁndings, the authors also
concluded that they had isolated pre-XCIRTT-hiPSCswhich carry
two Xa and express MECP2 in a biallelic manner.
INCONSISTENCIES BETWEEN THE XCI STATUS OF
RTT-hiPSCs
The generation of RTT-hiPSCs with different XCI status is worth
reviewing (Marchetto et al., 2010; Amenduni et al., 2011; Ananiev
et al., 2011; Cheung et al., 2011; Kim et al., 2011; Pomp et al.,
2011). These differences are unlikely to be due to the starting
ﬁbroblasts as identical ﬁbroblast cell lines were often used, as were
similar culture conditionsusingbFGF/KOSRonmouse embryonic
ﬁbroblasts (MEFs; Table 1). One exception was that Muotri and
colleagues used feeder-free conditions with mTeSR1 on matrigel
(Marchetto et al., 2010). Whether this subtle difference can affect
the XCI status of RTT-hiPSCs remains to be determined, although
it is worth noting that the mTeSR1/matrigel conditions act as a
substitute for the bFGF/KOSR conditions (Ludwig et al., 2006).
Finally, reprogramming methods were similar between the differ-
ent groups, as all used retroviral transduction of OCT4, SOX2,
KLF4, and c-MYC, consistent with the lack of correlation between
reprogrammingmethods andXCI status of female hiPSCs (Tchieu
et al., 2010; Ananiev et al., 2011). Therefore, the starting cell type,
culture conditions, and reprogramming methods were similar and
are not strong candidates to explain the differences observed in the
XCI status of RTT-hiPSCs.
Although we have opted to use the post- and pre-XCI nomen-
clature for this review, it is worth revisiting the classiﬁcation
system proposed by Lee and colleagues (Silva et al., 2008). Most
RTT-hiPSCs reported are either Class II or III as they are post-
XCI, exhibit non-random XCI skewing resulting in non-random
monoallelic expression of MECP2 and maintain this expression
pattern upon differentiation into neurons (Amenduni et al., 2011;
Ananiev et al., 2011; Cheung et al., 2011; Pomp et al., 2011). XCI
marker analyses have identiﬁed examples of RTT-hiPSCs that can
be classiﬁed as Class II or III based on XIST RNA-FISH and/or
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Table 1 | Summary of RTT-fibroblasts reprogrammed, method of reprogramming, and the outcome of XCI status in RTT-hiPSCs.
Group Fibroblasts reprogrammed Reprogramming method Culture condition XCI status of RTT-hiPSCs
Muotri (Marchetto
et al., 2010)
GM11270 (R306C), GM11272
(1155del32), GM16548 (Q244X),
GM17880 (T158M)
Retroviral (OCT4, SOX2, KLF4,
c-MYC )
Feeder free – mTesr1 Pre- and post-XCI
Ellis (Cheung et al.,
2011)
3–4 (Exon 3–4 delete), GM11270
(R306C), GM17880 (T158M)
Retroviral (OCT4, SOX2, KLF4,
c-MYC )
bFGF/KOSR MEFs Post-XCI
Renieri (Amenduni
et al., 2011)
CDKL5 (Q347X), CDKL5 (T288I) – male Retroviral (OCT4, SOX2, KLF4,
c-MYC )
bFGF/KOSR MEFs Post-XCI
Park (Kim et al.,
2011)
GM07928 (E235fs), GM11270 (R306C),
GM16548 (Q244X), GM17567 (X487X),
GM17880 (T158M)
Retroviral (OCT4, SOX2, KLF4,
c-MYC )
bFGF/KOSR MEFs Pre- and post-XCI
Colman (Pomp et al.,
2011)
GM11272 (1155del32), GM17880
(T158M)
Retroviral (OCT4, SOX2, KLF4,
c-MYC, ±TERT )
bFGF/KOSR MEFs Post-XCI
Lentiviral (OCT4, SOX2, NANOG,
LIN28 )
2i+LIF Pre-XCI
Chang (Ananiev
et al., 2011)
GM17880 (T158M), GM07982 (V247X),
GM11270 (R306C), RS0502 (R294X)
Retroviral (OCT4, SOX2, KLF4,
c-MYC ) Lentiviral (OCT4, SOX2,
NANOG, LIN28 )
bFGF/KOSR MEFs Post-XCI
All ﬁbroblasts reprogrammed are from female RTT-patients carrying a heterozygous mutation (indicated in parenthesis) in MECP2 unless speciﬁed. Nomenclature of
cell lines beginning with “GM” are from the Coriell Cell Bank.
H3K27me3 IF (Cheung et al., 2011; Kim et al., 2011; Pomp et al.,
2011), while other studies cannot conclusively place their RTT-
hiPSCs within Class II or III (Amenduni et al., 2011; Ananiev
et al., 2011). On the other hand, the pre-XCI RTT-hiPSCs reported
by Park and colleagues lacked H3K27me3 marks and expressed
MECP2 twofold compared to male hESCs, consistent with a Class
I assignment (Kim et al., 2011). However, this approach does not
exclude the possibility of Class III hiPSCs that have lost XCI marks
resulting in reactivation of X-linked genes (Silva et al., 2008).
Likewise, the undifferentiated pre-XCI RTT-hiPSCs reported by
Muotri and colleagues lacked XCI marks, such as XIST RNA and
H3K27me3, and expressed MECP2 in a biallelic manner (Marche-
tto et al., 2010). Upon differentiation, the RTT-hiPSCs initiated
XCI by upregulating XCI marks and exhibited a mosaic expres-
sion of WT and mutant MECP2 consistent with a Class I hiPSC.
However, the apparent non-random skewing revealed by the AR
assay in the RTT-hiPSC-derived neurons revealed a pattern char-
acteristic of aClass II/III hiPSC.Overall, these data remain difﬁcult
to interpret. Further experiments to conclusively demonstrate the
isolationof pre-XCIRTT-hiPSCs equivalent toClass I are required.
EVALUATION OF XCI IN RTT-hiPSCs
Given the epigenetic ﬂuidity that exists in hPSCs in the context of
XCI (Hall et al., 2008; Shen et al., 2008; Silva et al., 2008; Dvash
et al., 2010; Lengner et al., 2010; Tchieu et al., 2010; Pomp et al.,
2011; Diaz Perez et al., 2012), it is critical to review how the XCI
status was determined in RTT-hiPSCs and review the strengths
and weaknesses of different technical approaches to accurately
evaluate XCI (Tables 2 and 3). The most common method of
determining the XCI status in RTT-hiPSCs was the evaluation of
XCI markers such as XIST by RNA-FISH and repressive chro-
matin marks and their mediators such as H3K27me3 and EZH2
by IF (Table 2). However, the evaluation of XCI based solely on
XIST RNA and/or chromatin marks and their mediators is insufﬁ-
cient to deﬁne the XCI status of hPSCs (Table 3). Another method
that has been used for evaluation of XCI in RTT-hiPSCs is the AR
assay, a method that measures the DNA methylation status of the
X-linked AR gene (Table 2; Allen et al., 1992). This method has
two advantages, (1) it measures DNA methylation,which is a likely
epigenetic candidate that maintains the Xi in a transcriptionally
repressed state in the absence of XISTRNA and other repressive
chromatinmarks,and (2) itmeasures the skewingof XCI (Table 3).
Although not demonstrated, it may be possible to identify pre-XCI
hPSCs with the AR assay, as they will display no signal indicative
of two unmethylated Xa.
The importance of XCI is its functional outcome on the expres-
sion status of X-linked genes. For these reasons, expression analy-
ses must be performed (Table 3). Preferably, expression analysis
is done in a quantitative and allele-speciﬁc manner such as direct
sequencing of cDNA or qRT-PCR using allele-speciﬁc primers at
the population level. More stringently, allele-speciﬁc expression
can be done at the single cell level by using antibodies (via IF)
or probes (via RNA-FISH) that can distinguish between the WT
or mutant allele. Whenever possible, it is preferable to measure
the expression of both WT and mutant alleles although, in some
cases, it may be difﬁcult to design primers/antibodies/probes that
can distinguish the two. Allele-speciﬁc expression analysis at the
population level is important to distinguish non-random monoal-
lelic expression of post-XCI RTT-hiPSCs from biallelic pre-XCI
RTT-hiPSCs. Although biallelic expression may represent pre-
XCI RTT-hiPSCs, the mix of two clones of post-XCI RTT-hiPSCs
that express alternative parental X-chromosomes would also show
the same expression proﬁle. This mixture of two clones could be
revealed by the presence of two different-sized peaks in the AR
assay. The clonality of pre-XCI RTT-hiPSCs could also be con-
ﬁrmed by subcloning multiple sublines to examine whether they
Frontiers in Psychiatry | Molecular Psychiatry March 2012 | Volume 3 | Article 24 | 8
Cheung et al. XCI in RTT-hiPSCs
Table 2 | Summary of RTT-hiPSCs generated to date and their XCI status as determined by different methods.
Group Techniques used for XCI evaluation XCI status of
RTT-hiPSCs
XIST -RNA (FISH) H3K27me3 (IF) AR assay Expression analysis Other
Muotri (Marchetto
et al., 2010)
hiPSCs – absent hiPSCs – absent hiPSCs – N/A hiPSCs – biallelic Pre-XCI*
Neurons – present Neurons –
present
Neurons – extreme skewing Neurons – monoal-
lelic
Ellis (Cheung et al.,
2011)
hiPSCs – mix hiPSCs – mix hiPSCs – extreme skewing hiPSCs – monoallelic Post-XCI
Neurons – N/A Neurons – N/A Neurons – extreme skewing Neurons – monoal-
lelic
Renieri (Amenduni
et al., 2011)
hiPSCs – N/A hiPSCs – N/A hiPSCs – extreme skewing hiPSCs – monoallelic Post-XCI
Neurons – N/A Neurons – N/A Neurons – N/A Neurons – N/A
Park (Kim et al.,
2011)
hiPSCs – N/A hiPSCs – absent
(pre-XC)/present
(post-XCI)
hiPSCs – N/A hiPSCs – biallelic
(pre-XC)/monoallelic
(post-XCI)
hiPSCs – EZH2
(qRT-PCR) – low
(pre-XCI)/high
(post-XCI)
Pre- and post-
XCI
Neurons – N/A Neurons – N/A Neurons – N/A Neurons – N/A
Colman (Pomp
et al., 2011)
hiPSCs – present hiPSCs – N/A hiPSCs – N/A hiPSCs – monoallelic Post-XCI**
Neurons – N/A Neurons – N/A Neurons – N/A Neurons – N/A
Chang (Ananiev
et al., 2011)
hiPSCs – N/A hiPSCs – N/A hiPSCs – extreme skewing hiPSCs – monoallelic hiPSCs – XIST
RNA SNP
Post-XCI
Neurons – N/A Neurons – N/A Neurons (progenitors) –
extreme skewing
Neurons – monoal-
lelic
*Muotri and colleagues isolated both pre- and post-XCI RTT-hiPSCs but focused on the former. **Colman and colleagues were able to isolate pre-XCI RTT-hiPSCs
after naïve conversion. N/A, experiment not performed.
Table 3 | Commonly used techniques to evaluate XCI status in hPSCs.
Method Description Advantages and disadvantages
XIST RNA (FISH) XIST RNA is required for the initiation of XCI and coats the Xi. This can
be detected by RNA-FISH as a punctate signal on the Xi.
Its absence (in hPSCs) is not directly correlated with
the XCI status.
Chromatin marks
and mediators
Repressive chromatin marks (H3K27me3, H4K20me1, MacroH2A) and
their mediators (EZH2, EED) accumulate on the Xi during XCI. These
marks can be detected via IF and appear as a punctate signal on the Xi.
Its absence (in hPSCs) is not directly correlated with
XCI status.
AR assay The X-linked AR gene contains a trinucleotide polymorphism in its ﬁrst
exon, which allows the two parental X-chromosomes to be
distinguished by PCR. Digestion with methylation sensitive enzymes
prior to PCR digests the unmethylated Xa. Genetic analyzers can be
used to quantitate the relative proportions of Xi.
Allows XCI skewing to be calculated.
Does not read out the unmethylated (active) X-
chromosome.
Only a single locus (Xq12) is being measured and
may not reﬂect the entire X-chromosome. Requires
polymorphism at the AR gene.
Allele-speciﬁc
expression
analysis
Determine the expression of the gene of interest in an allele-speciﬁc
manner. This can be done at a population level via direct sequencing of
cDNA or qRT-PCR using allele-speciﬁc primers. This can also be done
at a single cell level via antibodies (IF) or probes (RNA-FISH) that can
distinguishWT and mutant proteins or transcripts, respectively.
Functional read out of XCI.
Only a single locus is being measured and may not
reﬂect entire X-chromosome.
Cot1 RNA FISH Cot1 RNA-FISH to visualize hnRNA transcription throughout the
nucleus. The Xi will be devoid of Cot1 RNA indicating a transcriptionally
silent compartment.
Functional read out of XCI.
Allows global transcription to be assessed.
May not detect small scale reactivation of X-linked
genes.
Conclusion of Xi presence is based on absence of
signal.
X-chromosome
wide expression
analysis
Determines the expression status of the entire set of genes on the
X-chromosome.
Functional read out of XCI.
Visualize transcriptional activity of entire set of X-linked
genes.
Allows identiﬁcation of three classes of hPSCs – pre-
XCI, post-XCI, and partial-XCI.
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contain identical or distinct retroviral transgene integration sites
by southern blot analysis.
Allele-speciﬁc expression analysis of MECP2 only measures the
XCI status of that particular locus and may not represent the status
of the entire the X-chromosome. Therefore, it may be worth-
while to use other approaches to measure the transcription level of
the entire X-chromosome. This includes Cot1 RNA-FISH which
highlight areas of actively transcribed heterogeneous nuclear RNA
(hnRNA; van den Berg et al., 2009). The Xi is devoid of Cot1 RNA
indicative of a transcriptionally silent compartment. This tech-
nique has been most widely used in the hESC literature (Hoffman
et al., 1987; Hall et al., 2008; Silva et al., 2008). However, Cot1
RNA-FISH may not detect small scale reactivation of X-linked
genes. Therefore, a more stringent method will be to perform X-
chromosome wide expression analysis via microarray to measure
the transcriptional activity of all X-linked genes (Table 3). It is
important to note that the detection of twofold differences from
the microarray inferred by male:female expression comparisons
could be difﬁcult and that allele-speciﬁc expression analysis (men-
tioned above) should be performed as independent validation.
Given that these X-chromosome wide expression analyses have
not been reported for RTT-hiPSC and their neuronal derivatives,
we conclude that the methods employed to date on RTT-hiPSCs
cannot unambiguously exclude the possibility of partial-XCI in
either the post- or pre-XCI RTT-hiPSCs.
Finally, it is informative to investigate the XCI status of RTT-
hiPSCs not only in their undifferentiated state but also upon
differentiation. Pre-XCIRTT-hiPSCs should initiateXCI upondif-
ferentiation and exhibit a random mode of XCI revealed by theAR
assay, accompanied by the upregulation of XCImarks such asXIST
RNA and H3K27me3 (Dhara and Benvenisty, 2004; Hall et al.,
2008; Silva et al., 2008;Dvash et al., 2010). Upon differentiation,X-
linked genes should be expressed in a random monoallelic fashion
(Dhara and Benvenisty, 2004) at the single cell level, which could
be identiﬁed byRNA-FISHor IF.Differentiation of post-XCIRTT-
hiPSCs, regardless of the presence or absence of XCI marks, will
show a continued presence or absence of XCI marks, respectively,
resulting in non-random XCI skewing and monoallelic expression
pattern of X-linked genes (Hoffman et al., 1987; Hall et al., 2008;
Shen et al., 2008; Silva et al., 2008; Liu and Sun, 2009; Dvash et al.,
2010; Lengner et al., 2010; Tchieu et al., 2010; Cheung et al., 2011;
Pomp et al., 2011; Diaz Perez et al., 2012). Altogether, the analy-
sis of XCI upon differentiation of RTT-hiPSCs into neurons will
be critical to conclusively demonstrate the isolation of pre-XCI
RTT-hiPSCs in comparison to post-XCI RTT-hiPSCs.
PROS AND CONS OF POST- AND PRE-XCI RTT-hiPSCs
The generation of both post- and pre-XCI RTT-hiPSCs offers
investigators twodifferent cell types to studyRTT (Marchetto et al.,
2010; Amenduni et al., 2011; Ananiev et al., 2011; Cheung et al.,
2011; Kim et al., 2011; Pomp et al., 2011). Post-XCI RTT-hiPSCs
are advantageous as they allow the generation of isogenic control
and mutant RTT-hiPSCs from the same patient (Amenduni et al.,
2011; Ananiev et al., 2011; Cheung et al., 2011; Pomp et al., 2011).
For disease phenotyping, healthy control hiPSCs are essential and
isogenic cells from the same patient eliminate genetic background
effects that exist between individuals that may have an affect on
subsequent phenotyping. Furthermore, isogenic RTT-hiPSCs may
respond to directed differentiation cues in amore uniformmanner
compared to hPSCs generated from different individuals (Osafune
et al., 2008; Hu et al., 2010). Directed differentiation of post-
XCI RTT-hiPSCs will yield homogeneous cultures of neurons that
express either WT or mutant MECP2 allowing simpler analysis of
a population of cells without inﬂuence from the opposite allele
being expressed as in pre-XCI RTT-hiPSCs (Cheung et al., 2011).
Finally, the generation of isogenic control andmutantRTT-hiPSCs
allow the mixing and matching of WT and mutant expressing cells
in different proportions which provides an opportunity to study
the effects of XCI skewing as observed in RTT patients (Archer
et al., 2007). Furthermore, it will also allow the mixing and match-
ing of different cell types such as neurons and glia to study the
non-cell autonomous effects of non-neuronal cell types in RTT
as has become apparent in the recent RTT literature (Ballas et al.,
2009; Maezawa et al., 2009; Maezawa and Jin, 2010; Lioy et al.,
2011).
However, there are also potential disadvantages to post-XCI
RTT-hiPSCs. From a biological standpoint, one could question
whether post-XCI RTT-hiPSCs are fully reprogrammed given that
the Xi did not reactivate. This is likely in part due to subopti-
mal culture conditions and reprogramming methods required to
capture and stabilize RTT-hiPSCs in a pre-XCI state (Nichols and
Smith, 2009; Hanna et al., 2010; Lengner et al., 2010; Diaz Perez
et al., 2012). Although post-XCI RTT-hiPSCs have been shown
to exhibit non-random monoallelic expression of MECP2, the
possibility that they have partial-XCI cannot be excluded (Amen-
duni et al., 2011; Ananiev et al., 2011; Cheung et al., 2011; Pomp
et al., 2011). Additionally, it is important to note that although
isogenic control and mutant post-XCI RTT-hiPSCs are described
as isogenic, they are not truly isogenic by the strictest deﬁnition
as illustrated by the following two points. First, all post-XCI RTT-
hiPSCs generated to date were reprogrammed by integrating viral
vectors (Amenduni et al., 2011; Ananiev et al., 2011; Cheung
et al., 2011; Pomp et al., 2011). Given that each RTT-hiPSC line
is expected to be an independent clone, they will harbor unique
vector integration sites. Therefore, methods of reprogramming
such as non-integrating viral vectors (Stadtfeld et al., 2008b; Seki
et al., 2010), non-replicative episomal vectors (Yu et al., 2009),
and/or mRNA- (Warren et al., 2010), miRNA- (Anokye-Danso
et al., 2011; Miyoshi et al., 2011), or protein- (Kim et al., 2009)
based reprogramming methods will be required to overcome this
limitation. Secondly, the process of reprogramming itself leads to
the accumulation of diverse abnormalities in the genome of hiP-
SCs (Mayshar et al., 2010; Gore et al., 2011; Hussein et al., 2011;
Laurent et al., 2011; Lister et al., 2011). Therefore, each hiPSC line
will carry unique abnormalities that may affect the subsequent
phenotype of each hiPSC line. It is thus imperative to study more
than one hiPSC line per individual, affected and/or unaffected, to
ensure the validity of any phenotypes.
Pre-XCIRTT-hiPSCs are advantageous because their differenti-
ation initiates randomXCI allowing generation of amosaic culture
of neurons expressing WT or mutant MECP2 (Marchetto et al.,
2010; Kim et al., 2011). This provides a clinically relevant system as
RTT patients are mosaic with respect to WT and mutant MECP2
expression. However, such a mosaic culture may introduce a new
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variable as one needs to ensure that all differentiation experiments
yield similar XCI skewing ratios. Furthermore, the mosaic cul-
ture creates difﬁculty when interpreting results, as any population
analysis reads out both WT and mutant MECP2 expressing cells.
One needs to perform single cell analysis and visualize WT and
mutant cells separately, such as by using C-terminus speciﬁc anti-
bodies of MECP2 that will not detect truncation mutations (i.e.,
1155del32; Marchetto et al., 2010). However, this may be difﬁcult
on the more common point mutations of MECP2 due to the lack
of mutation-speciﬁc antibodies (Percy et al., 2007;Marchetto et al.,
2010; Cheung et al., 2011). Similar to the case of post-XCI RTT-
hiPSCs, althoughpre-XCIRTT-hiPSCs have been shown to exhibit
biallelic expression of MECP2, it cannot be excluded that pre-XCI
hiPSCs may have partial-XCI (Marchetto et al., 2010; Kim et al.,
2011). Nevertheless, Muotri and colleagues have extensively stud-
ied RTT phenotypes in pre-XCI RTT-hiPSC-derived neurons, and
reported defects in glutamatergic synapse numbers, spine density,
soma size, calcium signaling, and electrophysiological properties
(Marchetto et al., 2010). Interestingly, Park and colleagues found a
defect in neuronal differentiation frompre-XCI RTT-hiPSCs (Kim
et al., 2011), which is novel in comparison to the RTT literature
(Bauman et al., 1995; Chen et al., 2001; Kishi and Macklis, 2004;
Marchetto et al., 2010; Ananiev et al., 2011) and warrants further
investigation. Reassuringly, this phenotype was also observed in
their mutant post-XCI RTT-hiPSCs (Kim et al., 2011). Both these
studies demonstrate the potential of using pre-XCI RTT-hiPSCs
for disease modeling (Marchetto et al., 2010; Kim et al., 2011).
IMPACT OF XCI IN OTHER DISEASES
XCI in female hiPSCs has implications in other X-linked diseases
including Fragile X Syndrome (FMR1), α-thalassemia (ATRX),
Cofﬁn-Lowry Syndrome (RSK2), DMD (DYSTROPHIN ), Lesch-
Nyhan Syndrome (HPRT ), and Wiskott Aldrich Syndrome
(WASP). In fact, many mental-disorder related genes are con-
centrated on the X-chromosome (Skuse, 2005; Gecz et al., 2009).
DMD-hiPSCs have been generated and were shown to be post-
XCI in a non-random pattern allowing the generation of isogenic
control and mutant hiPSCs (Tchieu et al., 2010). HiPSCs have
also been generated from Fragile X Syndrome patients although
they were from male patients (Urbach et al., 2010). Perhaps
more intriguing is the possibility of generating isogenic control
and mutant post-XCI hiPSCs from carriers of X-linked diseases
who otherwise may be apparently healthy. This will be particu-
lar advantageous in cases in which the proband is a male but has
an unaffected mother and/or sisters who are carriers. Finally, the
generation of post-XCI hiPSCs poses a unique opportunity for cel-
lular therapy as a mosaic population of cells from a female patient
can be reprogrammed into post-XCI hiPSCs in which hiPSCs can
expressing the WT allele be used as a source for normal cells for
cellular therapy purposes (Tchieu et al., 2010).
In the case of autosomal disorders, although XCI would not
affect the primary gene of interest, female post-XCI hiPSCs gen-
erated from these patients may have a completely different X-
chromosome transcriptome as each hiPSC line will carry either
a paternal or maternal Xa. Therefore any heterozygous X-linked
geneswill be differentially expressed. Itmay be important to screen
post-XCI hiPSCs, generated from female patients carrying an
autosomal disorder, as well as unaffected females, by the AR assay
to ensure that multiple post-XCI hiPSC lines used for downstream
applications carry the same parental Xi.
CONCLUSION AND FUTURE REMARKS
The generation of hiPSCs from RTT patients represents an inex-
haustible source for in vitro derived patient-speciﬁc neurons,
assuming that RTT-hiPSCs can be expanded indeﬁnitely with a
normal karyotype and stable genome. These neurons are useful
for investigating the pathogenesis of RTT and have potential for
use in drug screens and identiﬁcation of novel compounds for
therapy (Marchetto et al., 2010; Amenduni et al., 2011; Ananiev
et al., 2011; Cheung et al., 2011; Kim et al., 2011; Pomp et al.,
2011). For this potential to be realized, efﬁcient protocols that
direct differentiation into adult stage neurons of deﬁned subtypes
may be required (Hansen et al., 2011). The X-linked nature of
MECP2 has prompted the extensive investigation of the XCI status
of RTT-hiPSCs. Both post- and pre-XCI RTT-hiPSCs have been
reported each with their own advantages and disadvantages for
subsequent use. However, given the variation in XCI status seen in
RTT-hiPSCs, it is imperative to accurately evaluate the XCI status
in hiPSCs generated from RTT patients. Indeed, the XCI status
of hiPSCs also has huge impact on other X-linked diseases, unaf-
fected females who may or may not carry X-linked mutations, and
perhaps also autosomal diseases.
To accurately evaluate the XCI status of RTT-hiPSCs, we pro-
pose the following workﬂow. RTT-hiPSCs should be screened ﬁrst
using the AR assay to distinguish potential pre-XCI RTT-hiPSCs
that will show no peaks from potential post-XCI RTT-hiPSCs that
retain an Xi as revealed by one peak. The AR assay is advanta-
geous as a screening method given its relative technical ease to
perform on a large number of samples. To conﬁrm the candidate
pre-XCI RTT-hiPSCs identiﬁed by the AR assay retain two Xa,
allele-speciﬁc expression analysis of MECP2 by cDNA sequenc-
ing, qRT-PCR, RNA-FISH, or IF in an allele-speciﬁc manner will
show a biallelic expression pattern. XCI marks will be absent as
revealed by XIST RNA-FISH or H3K27me3 IF. It is important
to differentiate candidate pre-XCI RTT-hiPSCs into neurons to
demonstrate randomXCI, as revealed by two equal peaks in theAR
assay, accompanied by upregulation of XCI marks. Allele-speciﬁc
expression analysis, preferably by RNA-FISH or IF at the single
cell level, will yield a random monoallelic expression of MECP2.
Only pre-XCI RTT-hiPSCs that meet these criteria will generate
the desired unskewed mix of neurons expressing either the WT or
mutant MECP2 allele. As these bona ﬁde pre-XCI RTT-hiPSCs are
passaged, it will be important to continue to assess their XCI status
periodically, by performing AR assays for example, to ensure they
are not transitioning into post- or partial-XCI RTT-hiPSCs.
The candidate post-XCI RTT-hiPSCs identiﬁed by presence of
one peak in the initial AR assay could be divided into two groups
with alternative parental X-chromosomes inactivated based on
the different peak size of the AR assay. This will ensure that
mutant and isogenic control RTT-hiPSCs can be isolated, and will
facilitate identiﬁcation of RTT-hiPSCs that express the Xu if the
starting ﬁbroblasts have been extensively passaged. Allele-speciﬁc
MECP2 expression analysis of post-XCI RTT-hiPSCs will show
non-random monoallelic expression and identify isogenic control
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andmutant RTT-hiPSCs. Post-XCIRTT-hiPSCswill be either pos-
itive or negative for XCI marks as revealed by XIST RNA-FISH or
H3K27me3 IF. Differentiation of post-XCI RTT-hiPSCs will pro-
duce neurons that maintain the non-random XCI skewing pattern
in AR assays and non-random monoallelic expression pattern of
MECP2 by allele-speciﬁc expression analysis by RNA-FISH or IF
at the single cell level. These post-XCI RTT-hiPSCs should also be
subjected to XCI analyses periodically upon passaging, for exam-
ple by AR assays, to ensure they do not transition into partial-XCI
that have reactivated large regions of the X-chromosome.
The possibility that reported post- and pre-XCI RTT-hiPSCs
may in fact exhibit partial-XCI has not yet been tested. Both post-
and pre-XCI RTT-hiPSCs do however recapitulate the expected
neuronal maturation and electrophysiological defects indicative
of RTT. To fully classify XCI in the RTT-hiPSCs, it would be infor-
mative to perform X-chromosome wide expression analysis using
microarrays. Nevertheless, the impact of a partial-XCI state on
disease phenotyping in vitro remains to be determined.
Finally, to facilitate the isolation and stable maintenance of
pre-XCI hPSCs that carry two Xa and are capable of initiating
random XCI upon differentiation, it is important to continue
to identify the optimal culture conditions that can capture this
naïve state (Nichols and Smith, 2009). Efforts are underway to
try to capture this pristine state of hPSCs by modifying oxygen
concentrations, addition of exogenous transcription factors, small
molecules, and/or using the 2i regimen, in which the latter has
been successfully applied in the mouse system (Ying et al., 2008;
Buecker et al., 2010; Hanna et al., 2010; Lengner et al., 2010; Diaz
Perez et al., 2012). Generation of pre-XCI hPSCs will provide an
invaluable in vitro system to study XCI in humans which will be
essential as the mouse may be not be quite as similar as once
thought (van den Berg et al., 2009, 2011; Fan and Tran, 2011;
Okamoto et al., 2011; Minkovsky et al., 2012).
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